<DOC>
	<DOCNO>NCT00182013</DOCNO>
	<brief_summary>The objective study compare safety effectiveness Risperidone , Olanzapine , Quetiapine treatment mania child adolescent Bipolar disorder 8 week extension phase . This exploratory , open-label study , seek determine evidence efficacy . The result study used generate hypothesis large study .</brief_summary>
	<brief_title>Open-Label Comparative Study Risperidone Versus Olanzapine Versus Quetiapine Mania Children Adolescents With Bipolar I Bipolar II Disorder</brief_title>
	<detailed_description />
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Males female age 6 18 year age Patient must diagnosis bipolar I bipolar II disorder currently display acute manic , hypomanic , mixed episode ( without psychotic feature ) accord DSMIV base clinical assessment confirm structured diagnostic interview ( Kidd Schedule Affective Disorders ) . Patients must initial score YMRS total score least 15 . Patient must able participate mandatory blood draw . Patient must able swallow pill . Patients chronic medical illness , DSMIV substance dependence within past 6 month , pregnant nursing female , serious risk suicide exclude study</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>